Chlamydia muridarum mutant CM-pGP3S as a novel attenuated live rectal vaccine protects against genital tract infection.

Introduction: Chlamydia trachomatis (CT) is a major sexually transmitted pathogen with severe complications. Using Chlamydia muridarum (CM) as a model, this study evaluates the attenuated mutant Chlamydia muridarum (CM-pGP3S) as a novel rectal vaccine to protect against genital tract infection and pathology.

Methods: Female C57BL/6 mice were rectally immunized with low (1×10³), middle (1×10⁵), or high (1×10⁷) doses of CM-pGP3S. Mice were challenged intravaginally with wild-type Chlamydia muridarum 63 days post-immunization. Protection was assessed via genital Chlamydia shedding, hydrosalpinx incidence (gross/histopathology), serum IgG, fecal IgA, and T cell responses. Gut microbiota stability was analyzed using qPCR.

Results: CM-pGP3S immunization significantly reduced CM-WT genital shedding duration (3-7 days vs. 21 days in controls, p < 0.01) and hydrosalpinx incidence (0% vs. 80% in controls, p < 0.01). Elevated systemic and mucosal immunity were observed, including higher serum IgG (1:100-1:1600 dilutions, p < 0.05-0.01) and fecal IgA (p < 0.05-0.01). CD4⁺ and CD8⁺ T cells exhibited increased IFN-γ (p < 0.01), while CD8⁺ T cells showed elevated TNF-α and IL-2 (p < 0.05). No colitis or significant gut microbiota disruption occurred post-immunization.

Discussion: Rectal CM-pGP3S vaccination induces robust transmucosal immunity, protecting against genital Chlamydia infection and pathology without gastrointestinal adverse effects. This highlights its potential as a safe and effective mucosal vaccine strategy to combat CT genital tract infections.